| 51 |
28580661 | B lymphocytes repress hepatic tumorigenesis but not development in Hras12V transgenic mice. | 2017 Sep 15 |
2 |
| 52 |
28751718 | Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. | 2017 Jul 28 |
1 |
| 53 |
28951258 | Ibrutinib suppresses alloantibody responses in a mouse model of allosensitization. | 2017 Dec |
3 |
| 54 |
29069762 | Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling. | 2017 Sep 22 |
1 |
| 55 |
29263930 | STAT3 mediates C6-ceramide-induced cell death in chronic lymphocytic leukemia. | 2017 |
1 |
| 56 |
26540627 | Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies. | 2016 Jan 25 |
1 |
| 57 |
26582643 | BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. | 2016 Apr |
2 |
| 58 |
26627823 | Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function. | 2016 Feb 5 |
5 |
| 59 |
26715645 | Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. | 2016 Mar |
4 |
| 60 |
26819453 | The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. | 2016 Jun 1 |
1 |
| 61 |
26880800 | Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. | 2016 Apr 15 |
5 |
| 62 |
27029059 | A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells. | 2016 May 3 |
2 |
| 63 |
27471620 | A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells. | 2016 Jun |
2 |
| 64 |
27564106 | Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes. | 2016 Oct 25 |
2 |
| 65 |
27813535 | Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells. | 2016 Nov 4 |
1 |
| 66 |
25730880 | Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. | 2015 Mar 3 |
3 |
| 67 |
26059659 | Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury. | 2015 Jun 10 |
1 |
| 68 |
26254443 | Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. | 2015 Sep 24 |
1 |
| 69 |
26348529 | Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice. | 2015 |
2 |
| 70 |
26637884 | Synergistic Cytotoxicity of Bendamustine and the BTK Inhibitor in a Mantle Cell Lymphoma Cell Line. | 2015 Dec |
2 |
| 71 |
24311722 | Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). | 2014 Feb 20 |
3 |
| 72 |
24316417 | The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss. | 2014 Mar |
2 |
| 73 |
24812669 | Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival. | 2014 Jun |
1 |
| 74 |
24915291 | Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. | 2014 Jun 26 |
3 |
| 75 |
25222877 | 4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies. | 2014 Oct 30 |
1 |
| 76 |
25271622 | Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. | 2014 Nov |
2 |
| 77 |
23359016 | Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. | 2013 |
4 |
| 78 |
23619564 | Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy. | 2013 Dec |
1 |
| 79 |
23136880 | Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus. | 2012 Nov 8 |
1 |